Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption.
Level 5 - mechanism / opinion, no new human data
Narrative review of drug mechanisms and development without systematic search or pooled clinical data
PubMed 35063734 · doi:10.1016/j.ejmech.2022.114111
What was done
This narrative review synthesized literature on the mechanism of cholesterol transport by Niemann-Pick C1-Like 1 (NPC1L1), outlined medicinal chemistry efforts to develop NPC1L1 inhibitors, and examined current challenges in the field.
What was found
The abstract reports no numerical findings or empirical data. It notes that ezetimibe remains the first and only approved NPC1L1 inhibitor for reducing cholesterol absorption in hypercholesterolemia for nearly two decades, indicating persistent difficulty in bringing new inhibitor candidates to clinical application.
Why it matters
Targeting NPC1L1 is a validated mechanism to lower serum cholesterol and mitigate heart disease risk. Documenting the structural and chemical challenges of NPC1L1 inhibition helps clarify why viable therapeutic alternatives to ezetimibe have been difficult to develop.
Limits
This is a narrative review presenting no new clinical or experimental data. The abstract provides no quantitative details, search methodology, or evaluation of specific pipeline compounds.
Cited by
- supports Zetia (ezetimibe) works by blocking the uptake and absorption of cholesterol.